Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Jettisons Japan Rights to Obesity Drug OBLEAN after Long Listing Limbo
Takeda Pharmaceutical is calling off its licensing accord with Amsterdam-headquartered Norgine for its obesity drug OBLEAN (cetilistat), which earned Japan approval in 2013 but has since been in a limbo for listing after being rebuffed by a key reimbursement panel…
To read the full story
Related Article
- MHLW Says Additional Data Needed for OBLEAN Listing
April 10, 2014
- Reimbursement Listing of OBLEAN Put on Hold, Faces Rare CSIMC Setback
November 15, 2013
- Takeda’s OBLEAN Near-Certain to Debut as Japan’s 1st Anti-Obesity Drug in 20 Years
September 2, 2013
- First Committee Recommends Approval of Takeda’s Anti-Obesity Drug OBLEAN, Other Products
August 26, 2013
BUSINESS
- Former Takeda CEO Yasuchika Hasegawa Dies at 80
September 11, 2026
- Takeda R&D Chief Plump to Retire in June 2027
September 11, 2026
- Lasker Win “Not the Finish Line” for Chugai Researchers; Next-Gen Drug Advances
September 11, 2026
- Daiichi Sankyo Wins 203 Billion Yen Lawsuit over Fortis Bid
September 11, 2026
- Silchester Emerges as Suzuken’s Top Shareholder with 10.03% Voting Stake
September 11, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…